alpha-MSH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
=== History === First formally described by Carl Linnaeus in 1753 with 19 species, the genus Viola bears his botanical authority, L. When Jussieu established the hierarchical system of families (1789), he placed Viola in the Cisti (rock roses), though by 1811 he suggested Viola be separated from these. However, in 1802 Batsch had already established a separate family, which he called Violariae based on Viola as the type genus, with seven other genera. Although Violariae continued to be used by some authors, such as Bentham and Hooker in 1862 (as Violarieae), most authors adopted the alternative name Violaceae, first proposed by de Lamarck and de Candolle in 1805, and Gingins (1823) and Saint-Hilaire (1824). However de Candolle also used Violarieae in his 1824 Prodromus.
=== Sequencing by synthesis === The objective for sequential sequencing by synthesis (SBS) is to determine the sequencing of a DNA sample by detecting the incorporation of a nucleotide by a DNA polymerase. An engineered polymerase is used to synthesize a copy of a single strand of DNA and the incorporation of each nucleotide is monitored. The principle of real-time sequencing by synthesis was first described in 1993 with improvements published some years later. The key parts are highly similar for all embodiments of SBS and includes (1) amplification of DNA (to enhance the subsequent signal) and attach the DNA to be sequenced to a solid support (an exception is the PacBio SMRT), (2) generation of single stranded DNA on the solid support, (3) incorporation of nucleotides using an engineered polymerase and (4) real-time detection of the incorporation of nucleotide The steps 3-4 are repeated and the sequence is assembled from the signals obtained in step 4. This principle of real-time sequencing-by-synthesis has been used for almost all massive parallel sequencing instruments, including 454, PacBio, IonTorrent, Illumina and MGI.
However, later on, within a more complex cellular environment, these highly hydrophobic LCRs became inappropriate or even toxic from a protein interaction perspective and have been selected against ever since. In addition, they further hypothesize that the very early protopeptides did not have a nucleic acid binding role, because DNA and RNA-binding LCRs are highly enriched in glycine, arginine and lysine, however, arginine and lysine are not among the amino acids of the proposed early genetic code.
Breakable PAGE SDS-PAGE (DPAGE, dissolvable PAGE), two-dimensional gel electrophoresis or chromatography is used for separation of MeCAT labelled proteins. Flow-injection ICP-MS analysis of protein bands or spots from DPAGE SDS-PAGE gels can be easily performed by dissolving the DPAGE gel after electrophoresis and staining of the gel. MeCAT labelled proteins are identified and relatively quantified on peptide level by MALDI-MS or ESI-MS.
In Lao cuisine, Lao coriander is used extensively in traditional Lao dishes such as 'mok pa' (steamed fish in banana leaf) and several coconut milk curries that contain fish or prawns. In China dill is called colloquially, 'huíxiāng' (茴香, perfume of Hui people), or more properly 'shíluó' (莳萝/蒔蘿). It is a common filling in 'baozi', 'jiaozi' and 'xianbing' and may be used as vegetarian with rice vermicelli, or combined with either meat or eggs. Vegetarian dill baozi are a common part of a Beijing breakfast. In baozi and xianbing, it often is interchangeable with non-bulbing fennel and the term 茴香 also may refer to fennel, similarly to caraway and coriander leaf, sharing a name in Chinese as well. Dill also may be stir fried as a potherb, often with egg, in the same manner as Chinese chives. In Northern China, Beijing, Inner-Mongolia, Ningxia, Gansu, and Xinjiang, dill seeds commonly are called 'zīrán' (孜然), but also 'kūmíng' (枯茗), 'kūmíngzi' (枯茗子), 'shíluózi' (莳萝子/蒔蘿子), 'xiǎohuíxiāngzi' (小茴香子) and are used with pepper for lamb meat. In the whole of China, 'yángchuàn' (羊串) or 'yángròu chuàn' (羊肉串), lamb brochette, a speciality from Uyghurs, uses cumin and pepper. In Cantonese-speaking regions such as Hong Kong and Macau, the leaves are more colloquially known as 刁草 (diu1 cou2), a partial calque of the English 'dillweed'; 'dill' transliterated into the otherwise unrelated 刁 diu1 and 'weed' translated as 草 cou2. In Taiwan, it is also commonly used as a filling in steamed buns (baozi) and dumplings (jiaozi). In Vietnam, the use of dill in cooking is regional.
Sources: en.wikipedia.org
A placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness. (NLM) An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo. (NCI) Placebo controlled study
Allergy to soy is common, and the food is listed with other foods that commonly cause allergy, such as milk, eggs, peanuts, tree nuts, and shellfish. The problem has been reported among younger children, and the diagnosis of soy allergy is often based on symptoms reported by parents and results of skin tests or blood tests for allergy. Only a few reported studies have attempted to confirm allergy to soy by direct challenge with the food under controlled conditions. It is very difficult to give a reliable estimate of the true prevalence of soy allergy in the general population. To the extent that it does exist, soy allergy may cause cases of urticaria and angioedema, usually within minutes to hours of ingestion. In rare cases, true anaphylaxis may also occur. The reason for the discrepancy is likely that soy proteins, the causative factor in allergy, are far less potent at triggering allergy symptoms than the proteins of peanut and shellfish. An allergy test that is positive demonstrates that the immune system has formed IgE antibodies to soy proteins. However, this is only a factor when soy proteins reach the blood without being digested, in sufficient quantities to reach a threshold to provoke actual symptoms. Soy can also trigger symptoms via food intolerance, a situation where no allergic mechanism can be proven. One scenario is seen in very young infants who have vomiting and diarrhoea when fed soy-based formula, which resolves when the formula is withdrawn.
butyl The alkyl functional group derived from either of the two isomers of butane, with the generic chemical formula –C4H9. It may occur as a substituent in organic compounds or exist independently as an ion or radical. In IUPAC nomenclature, the presence of a butyl substituent is indicated with the prefix butyl in the name of the compound, or with the abbreviation Bu in chemical formulae; e.g. butyl alcohol (butanol), which may occur in any of five different isomeric forms depending on the arrangement of the four carbon atoms, is often written with the generic formula CH4CH9OH or BuOH.
Maria Atalioti, Chief Inspector, Sovereign Base Areas Police, Cyprus. For services to Policing, Diversity and Inclusion in the Sovereign Base Areas. Elliott Forbes, Deputy Commissioner, Royal Anguilla Police Force. For services to Policing in Anguilla.
Sources: en.wikipedia.org
=== Starting stage === Loading: The first amino acid is activated with ATP as a mixed acyl-phosphoric acid anhydride with AMP by the A-domain and loaded onto the serine-attached 4'-phospho-pantethine (4'PP) sidechain of the PCP-domain catalyzed by the PCP-domain (thiolation). Some A domains require interaction with MbtH-like proteins for their activity. Sometimes the amino group of the bound amino acid is formylated by an F-domain or methylated by an NMT-domain.
== Medical uses == Seven controlled efficacy trials were conducted of vilazodone for treatment of major depressive disorder. Five of these trials showed no significant influence of vilazodone over placebo on depressive symptoms. In the remaining two trials, small but significant advantages of vilazodone over placebo were found. According to these two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment. After eight weeks it resulted in a 13% greater response than placebo. Remission rates, however, were not significantly different versus placebo. According to the US Food and Drug Administration (FDA) in 2011, "it is unknown whether vilazodone has any advantages compared to other drugs in the antidepressant class." A 2019 review stated that "present studies do not suggest the superiority of vilazodone compared with other antidepressants." Development of vilazodone for generalized anxiety disorder has been stopped as of 2017. While there is tentative evidence of a small benefit in generalized anxiety disorder, there is a high rate of side effects.
Their relationship is strained as Cain urges a firmer stance against the refugees and threats in town and threatens to take control from Jenna. The Homestead comes under direct attack and key residents are killed. Cain agitates the Homesteaders to turn against Jeff as Jeff questions Jenna's leadership. A radical religious sect in town led by a man called Father Burnham, who has a few congregants among the Homesteaders, claims Ian Ross promised their church a quarter of the Homestead's supplies in the event of a collapse. He allies with Masterson and Raven Rock to agitate outsiders against the Homesteaders. The city government engages in skirmishes with the Homesteaders to test their defenses. Tara becomes disillusioned with Jenna also and she and Jeff consider whether to try to take over the Homestead. They reach a breaking point after their son is injured by a snakebite. Masterson and Bing invite Jeff to join their side. Burnham tries to convince members of his congregation who are Homesteaders to turn against Jenna. As threats grow, the Homesteaders wrestle with moral choices as they try to prepare for an inevitable attack by Raven Rock. They try to recruit people from town to fight in exchange for food. Abe clashes with Jeff, who is trying to determine how best to lead his family. As the Homesteaders anticipate the impending attack, various members must decide whose side they are on and what they will do.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.